Blue Note Therapeutics, Inc., today announced the closing of a Series A financing round of $26.25 million. Proceeds will allow the company to scale the organization and fund near-term clinical trials of its lead prescription digital therapeutic (PDT), which will potentially improve the treatment of cancer. The capital will also support the development of Blue Note’s pipeline assets. The Series A financing was led by JAZZ Venture Partners and joined by Summer VC. [Read more…] about Blue Note Therapeutics raises $26M to help treat cancer-related distress via cognitive behavioral stress management (CBSM)
Today, the U.S. Food and Drug Administration is warning the public not to use medical devices marketed to consumers that claim to help assess, diagnose or manage head injury, including concussion, traumatic brain injury (TBI) or mild TBI. [Read more…] about The FDA warns consumers not to use unapproved apps and devices to diagnose concussion
During Expo Day selected Summit Partners and Sponsors showcased their latest initiatives and solutions.
- Franck Tarpin-Bernard, Managing Director of Scientific Brain Training (SBT), discussed new partnerships following their ISO 13485 certification for medical devices — cognitive remediation.
- Jessica Poulin, Strategic Operations Manager at the Arrowsmith Program, presented plans to better equip 100+ schools helping students with special needs.
These presentations took place at the 2016 SharpBrains Virtual Summit: Reinventing Brain Health in the Digital Age (December 6–8th, 2016).